|
Shionogi USA in the News
Press releases
August 13, 2009 -- Shionogi-GSK acknowledges position of European AIDS patient advocacy groups to revise protocol for Phase Ilb study for S/GSK1349572
July 21, 2009 -- Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study
February 18, 2009 -- Shionogi announces positive top-line efficacy results from year-long studies of velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity
October 27, 2006 -- Shionogi Discontinues Development of S-5751, a Prostaglandin D2 Receptor Antagonist
August 14, 2006 -- GlaxoSmithKline and Shionogi Complete Initial Clinical Study for HIV Integrase Inhibitor
July 10, 2006 -- Shionogi announces positive results from a Phase IIa study of S-2367, a novel neuropeptide Y5 receptor antagonist for the treatment of Obesity
July
10, 2002 -- Results of first human trial of a new class of anti-HIV drugs
reported by Shionogi-GSK
October
23, 2001 -- Final agreement reached on GSK-Shionogi joint venture
July
24, 2001 -- GSK and Shionogi to enter global multi-product development
and commercialization alliance
May
14, 2001 -- Establishment of Shionogi USA, Inc.
Shionogi
& Co., LTD, Press Releases
Shionogi
& Co., LTD, Financial Data
Shionogi
& Co., LTD, Annual Report
|
|
